Development of surrogate biomarkers for supporting clinical trials of human leptospirosis vaccines - luna bioscience, INC., a connecticut-based company spun out from yale university, is dedicated to…

Active Grant Awarded

Award ID
R41AI197598
Recipient
Awarding agency
Obligated
$300,239

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 18% complete
Place of performance
Westport, CT 06880, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Luna Bioscience, Inc. a $300,239 grant on July 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855), Grant R41AI197598.

The award funds development of surrogate biomarkers to support clinical trials of human leptospirosis vaccines. The work develops in vitro assays that measure IgG antibody inhibition of virulence-modifying (VM) protein functions, namely DNase activity, target cell binding, and cytotoxicity, using purified IgG from vaccinated dogs and hamsters. The second aim benchmarks these markers against lethal challenge with various Leptospira interrogans serovars in hamsters, after both vaccination and passive transfer of immune versus control sera. Success is stated to yield surrogate markers of efficacy that can support human clinical trials.

Luna Bioscience, Inc., a Connecticut-based company spun out from Yale University, is the recipient. Place of performance is Westport, CT 06880, USA. The period runs from the July 14, 2026 award date to an ultimate completion date of June 30, 2028. The assistance type is Grant.

Description

Development of surrogate biomarkers for supporting clinical trials of human leptospirosis vaccines - luna bioscience, INC., a connecticut-based company spun out from yale university, is dedicated to developing a vaccine to prevent human leptospirosis, a significant zoonotic bacterial disease. Leptospirosis affects over 1 million people annually with a high fatality rate of 5-20%. This project addresses the urgent need for a safe and effective human leptospirosis vaccine by creating reliable surrogate markers for vaccine-induced protection. The innovative aspect of this project is the development of simple in vitro tests to predict vaccine efficacy based on a new virulence modifying (VM) protein-based vaccine candidate, backed by preliminary data showing protection in animal models. There is currently no pan-effective human leptospirosis vaccine. Existing animal vaccines are unsuitable for humans due to efficacy and safety concerns. This project aims to close the GAP by developing surrogate markers to predict vaccine efficacy, focusing on the VM protein family. We hypothesize that antibodies induced by VM protein vaccines will provide protective immunity, and in vitro tests based on antibody interruption of VM protein functions (dnase activity, target cell binding, cytotoxicity) will predict this immunity. The specific aims are to (1) develop in vitro assays measuring IGG antibody inhibition of VM protein functions, using purified IGG from vaccinated dogs and hamsters, and (2) benchmark these markers against lethal challenge with various leptospira interrogans serovars in hamsters after both vaccination and passive transfer of immune VS. Control sera. Success will yield surrogate markers of efficacy that can support human clinical trials and potentially yield a leptospirosis vaccine with important domestic and american military health implications, as well as creating new markers for luna's leptospirosis products in low and middle-income countries (LMICS) and high- income countries with specific populations at risk. Key milestones include the identification of surrogate markers predicting protective immunity, and the development of in vitro tests correlating with protective immunity in the hamster model. This phase I project will be the basis for future collaboration with contract development and manufacturing organizations (CDMOS) to develop a cgmp-compatible manufacturing process and an analytical assay portfolio. Luna bioscience aims to first commercialize a VM protein-based leptospirosis vaccine for dogs, with assays to predict vaccine efficacy critical for FDA IND submission for human trials. By addressing these aims, the project will lay the foundation for a new effective vaccine against human leptospirosis, filling a significant unmet medical need.

Quick answers

Who received award R41AI197598?

R41AI197598 was awarded to Luna Bioscience, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 14, 2026.

How much is award R41AI197598 worth?

$300,239 has been obligated on R41AI197598.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award